GlaxoSmithKline
NEWS
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
The drugs in question bring in about $200 million annually.
The FDA is reviewing the sNDA under the Real-Time Oncology Review (RTOR) pilot program, which could speed up the process for potential approval.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The brands Stada is picking up include venous treatment Venoruton, Coldrex for colds, Cetebe vitamin C supplements, Mebucaine for sore threats and Tavegyl for allergies, among others.
Immatics is eligible for more than $550 million in various commercial milestone payments for each product as well as additional royalties.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
A number of new medications stand a shot at early regulatory approval thanks to the U.S. Food and Drug Administration’s priority review program.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
JOBS
IN THE PRESS